APA (7th ed.) Citation

Kim, B., Choi, C. H., Ngoi, N., Tan, D., & Kim, J. (2024). Preliminary efficacy of pembrolizumab plus lenvatinib in recurrent clear cell gynecological cancer: Phase II LARA trial (GCGS-OV4/APGOT-OV3). Journal of Gynecologic Oncology, 35, 31. https://doi.org/10.3802/jgo.2024.35.S2.P21

Chicago Style (17th ed.) Citation

Kim, Byoung-Gie, Chel Hun Choi, Natalie Ngoi, David Tan, and Jae-Weon Kim. "Preliminary Efficacy of Pembrolizumab Plus Lenvatinib in Recurrent Clear Cell Gynecological Cancer: Phase II LARA Trial (GCGS-OV4/APGOT-OV3)." Journal of Gynecologic Oncology 35 (2024): 31. https://doi.org/10.3802/jgo.2024.35.S2.P21.

MLA (9th ed.) Citation

Kim, Byoung-Gie, et al. "Preliminary Efficacy of Pembrolizumab Plus Lenvatinib in Recurrent Clear Cell Gynecological Cancer: Phase II LARA Trial (GCGS-OV4/APGOT-OV3)." Journal of Gynecologic Oncology, vol. 35, 2024, p. 31, https://doi.org/10.3802/jgo.2024.35.S2.P21.